We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed (CARVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01121458
Recruitment Status : Completed
First Posted : May 12, 2010
Last Update Posted : June 10, 2013
Information provided by (Responsible Party):
Subhash Banerjee, North Texas Veterans Healthcare System

Brief Summary:

Pulmonary arterial hypertension (PAH) is a rare blood vessel disorder of the lung in which the pressure in the pulmonary artery (PA) rises above normal levels and may become life threatening. PAH is frequently misdiagnosed and has often progressed to late stage by the time it is accurately diagnosed. PAH has been historically chronic and incurable with a poor survival rate. However, new treatments are available which have significantly improved prognosis. Right-heart catheterization (RHC) is the most accurate and useful test for PAH, and the only test that directly measures the pressure inside the PA. It is performed in all patients at least once, to get a definitive diagnosis of PAH.

The most commonly used medication for this purpose is intravenous nitroprusside, however this medication in about 25-30% of patients is not well tolerated as it cause fast heart rates, which is not well tolerated by patients with pulmonary hypertension and/or heart failure. The CARVE study assesses the effect of Clevidipine, an ultra-short acting vasoselective calcium antagonist, on pulmonary vascular resistance (PVR) and its utility for pulmonary vasoreactivity testing during right heart catheterization (RHC) of patients with pulmonary hypertension (PAH).

Condition or disease Intervention/treatment Phase
Hypertension, Pulmonary Drug: Clevidipine Phase 4

Detailed Description:

CARVE is a Phase 4 open-label descriptive observational trial in PAH patients undergoing invasive vasoreactivity testing in the cath lab at the Dallas VA Medical Center. Patients clinically indicated for RHC and assessment of pulmonary artery vasoreactivity will be enrolled if they meet the inclusion/exclusion criteria. The study will involve the following tests:

  1. Performance of clinically indicated RHC with assessment of pulmonary hypertension and pulmonary vascular resistance (PVR).
  2. Performance of clinically indicated pulmonary vasoreactivity assessment with IV Nitroprusside (standard of care)
  3. For patients who are responsive to Nitroprusside, or those who have an inconclusive result because of intolerability to Nitroprusside, pulmonary vasoreactivity assessment with study drug (IV) will be conducted.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed (CARVE)
Study Start Date : September 2009
Actual Primary Completion Date : April 2013
Actual Study Completion Date : April 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Clevidipine

Intervention Details:
  • Drug: Clevidipine
    The clevidipine infusion is to be administered via IV infusion at a starting dose of 0.5 mg/hour. The dose may be doubled every three (3) minutes to a maximum dose of 32 mg/hr as tolerated, until a 20% reduction in PVR is achieved or until the patient experiences hypotension (SBP< 80 mmHg), hypertension (SBP>150 mmHg), tachycardia (120 beats per minute), bradycardia (<50 beats per minute), or symptoms of hypotension or ischemia (chest pain, anxiety, nausea, vomiting), allergic reaction (hives, urticaria) or other adverse event. Clevidipine infusion may be terminated at any time for a safety reason or at the investigator's discretion.
    Other Name: Cleviprex

Primary Outcome Measures :
  1. Percent reduction in PVR with clevidipine in (1) nitroprusside responders and (2) patients with indeterminate nitroprusside reactivity tests [ Time Frame: During right heart catheterization (1-2 hours) ]

Secondary Outcome Measures :
  1. Efficacy/ safety measured by % reduction in PVR with clevidipine in patients with indeterminate reactivity tests & total study population;%patients with successful 20% reduction in PVR; SAE & adverse hemodynamic response to clevidipine during procedure [ Time Frame: During right heart catheterization (1-2 hrs) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Provide written informed consent before initiation of any study related procedures.
  • 21 years of age or older
  • Referred for clinically indicated pulmonary vascular resistance assessment
  • Presence of pulmonary hypertension by non-invasive testing
  • Patients referred for RHC and vasoreactivity testing

Exclusion Criteria:

  • Patient with baseline SBP < 100 mmHg
  • Patient with HR>120 beats/minute
  • Patients with severe or valvular heart disease
  • Patients with an acute coronary syndrome
  • Patients with a creatinine clearance < 30 ml/min
  • Patients with class IV congestive heart failure
  • Patients with platelet count < 100,000 per cc3
  • Patients with hemoglobin < 10g/dl
  • Patient with INR > 1.5
  • Patients with positive pregnancy test - women between 21 and 60 years of age
  • Patients with known or suspected allergy to study drug or study drug components, including allergy to soybeans, soy products, eggs, or egg products
  • Patients with defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia
  • Patients with contraindications to the use of IV nitroprusside
  • Patients with diagnosed or suspected intra-cardiac or systemic arteriovenous shunts
  • Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 3 months of randomization.
  • Other medical conditions that, in the opinion of the investigator, preclude participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01121458

Layout table for location information
United States, Texas
VA North Texas Health Care System
Dallas, Texas, United States, 75216
Sponsors and Collaborators
North Texas Veterans Healthcare System
Layout table for investigator information
Principal Investigator: Subhash Banerjee, MD North Texas Veterans Healthcare System
Layout table for additonal information
Responsible Party: Subhash Banerjee, Chief- Division of Cardiology, North Texas Veterans Healthcare System
ClinicalTrials.gov Identifier: NCT01121458    
Other Study ID Numbers: Dallas VA #09-041
First Posted: May 12, 2010    Key Record Dates
Last Update Posted: June 10, 2013
Last Verified: June 2013
Keywords provided by Subhash Banerjee, North Texas Veterans Healthcare System:
pulmonary artery
vascular resistance
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs